This study shows granzyme B-responsive imaging predicts immunotherapy success in triple-negative breast cancer, indicating its potential to optimize treatment plans.
Motivation: It is of great significance to predict the efficacy of immunotherapy at an early stage and avoid over-treatment of patients with low immune response. Goal(s): Using molecular imaging technology to monitor the immunotherapy-related biomarkers is expected to predict the therapeutic effect of TNBC immunotherapy at an early stage. Approach: The granzyme B-responsive MR/NIR fluorescent probe was constructed for molecular imaging. Results: The MR/NIR fluorescence imaging showed that the probe was activated by granzyme B in tumor with immunotherapy or chemotherapy combined with immunotherapy. Impact: Early prediction of the efficacy of immunotherapy is of great significance for optimizing the treatment plan in time and avoiding overtreatment of patients with low response.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: